Collegium Pharmaceutical Inc (COLL):企業の財務・戦略的SWOT分析

◆英語タイトル:Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1665
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Collegium Pharmaceutical Inc (COLL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium’s other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Canton, Massachusetts, the US.

Collegium Pharmaceutical Inc Key Recent Developments

Feb 27,2020 Collegium reports full-year 2019 revenue of $296.7 million
Feb 10,2020 Collegium Pharmaceutical announces Proposed Convertible Senior Notes Offering
Feb 07,2020 Assertio to divest US rights to Nucynta to Collegium for $375m
Jan 07,2020 Collegium provides 2020 Financial Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Collegium Pharmaceutical Inc – Key Facts
Collegium Pharmaceutical Inc – Key Employees
Collegium Pharmaceutical Inc – Key Employee Biographies
Collegium Pharmaceutical Inc – Major Products and Services
Collegium Pharmaceutical Inc – History
Collegium Pharmaceutical Inc – Company Statement
Collegium Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Collegium Pharmaceutical Inc – Business Description
Product Category: Nucynta
Performance
Product Category: Xtampza ER
Performance
R&D Overview
Collegium Pharmaceutical Inc – Corporate Strategy
Collegium Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Collegium Pharmaceutical Inc – Strengths
Collegium Pharmaceutical Inc – Weaknesses
Collegium Pharmaceutical Inc – Opportunities
Collegium Pharmaceutical Inc – Threats
Collegium Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Collegium Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 27, 2020: Collegium reports full-year 2019 revenue of $296.7 million
Feb 10, 2020: Collegium Pharmaceutical announces Proposed Convertible Senior Notes Offering
Feb 07, 2020: Assertio to divest US rights to Nucynta to Collegium for $375m
Jan 07, 2020: Collegium provides 2020 Financial Guidance
Nov 06, 2019: Collegium reports third quarter 2019 financial results
Aug 07, 2019: Collegium reports second quarter 2019 financial results
May 08, 2019: Collegium reports first quarter 2019 financial results
Apr 02, 2019: Collegium Pharmaceutical names Richard Malamut as Chief Medical Officer
Feb 27, 2019: Collegium reports fourth-quarter and full-year 2018 financial results
Jan 07, 2019: Collegium Provides Full-Year 2019 Financial Guidance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Collegium Pharmaceutical Inc, Key Facts
Collegium Pharmaceutical Inc, Key Employees
Collegium Pharmaceutical Inc, Key Employee Biographies
Collegium Pharmaceutical Inc, Major Products and Services
Collegium Pharmaceutical Inc, History
Collegium Pharmaceutical Inc, Subsidiaries
Collegium Pharmaceutical Inc, Key Competitors
Collegium Pharmaceutical Inc, Ratios based on current share price
Collegium Pharmaceutical Inc, Annual Ratios
Collegium Pharmaceutical Inc, Annual Ratios (Cont...1)
Collegium Pharmaceutical Inc, Interim Ratios
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Collegium Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Collegium Pharmaceutical Inc, Performance Chart (2015 - 2019)
Collegium Pharmaceutical Inc, Ratio Charts
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Collegium Pharmaceutical Inc (COLL):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tenaska Inc:発電所・企業SWOT分析
    Tenaska Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • EnCana Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    EnCana Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary EnCana Corp (EnCana) is an oil and gas producer. The company explores, develops, produces and markets natural gas, oil and natural gas liquids (NGLs). Its major resource plays include Montney, Duvernay, …
  • Merge Healthcare Inc:医療機器:M&Aディール及び事業提携情報
    Summary Merge Healthcare Inc (Merge Technologies), a subsidiary of International Business Machines Corp, is a medical technology company that offers advanced solutions specifically designed for healthcare. The company's solutions include cardiology, orthopedics, interoperability, radiology, eye care …
  • Herantis Pharma Plc (HRTIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Herantis Pharma Plc (Herantis Pharma) is a drug development company that offers regenerative medicine for neurodegenerative diseases. The company's pipeline products include CDNF for amyotrophic lateral sclerosis, CDNF for Parkinson’s disease and lymfactin for secondary lymphedema. Its lymfa …
  • Gulf Resources Inc (GURE):企業の財務・戦略的SWOT分析
    Gulf Resources Inc (GURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Galderma SA:企業の戦略的SWOT分析
    Galderma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Murphy Oil Corporation:企業の戦略・SWOT・財務分析
    Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report Summary Murphy Oil Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • International Consolidated Airlines Group, S.A.:企業の戦略・SWOT・財務情報
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Barratt Developments Plc:企業の戦略・SWOT・財務情報
    Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report Summary Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Ryosan Company, Ltd:企業の戦略・SWOT・財務分析
    Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report Summary Ryosan Company, Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ShinMaywa Industries, Ltd.:企業の戦略・SWOT・財務情報
    ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ShinMaywa Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Raia Drogasil SA:企業の戦略・SWOT・財務分析
    Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report Summary Raia Drogasil SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cordis Corp-医療機器分野:企業M&A・提携分析
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …
  • National Institute on Drug Abuse:製薬・医療:M&Aディール及び事業提携情報
    Summary National Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a research institute that provides drug abuse and addiction services. The institute offers services in drugs of abuse such as bath salts, cocaine, heroin, inhalants, alcohol, club drugs, methamphetamine …
  • Nichirei Corp (2871):企業の財務・戦略的SWOT分析
    Nichirei Corp (2871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Mitchells & Butlers plc:企業の戦略・SWOT・財務分析
    Mitchells & Butlers plc - Strategy, SWOT and Corporate Finance Report Summary Mitchells & Butlers plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Academic Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Academic Medical Center (AMC), a subsidiary of University of Amsterdam is a medical center that offers research and educational services. The center offers services such as treatment of patients, medical research and medical education. It provides medical treatments and services for various …
  • Randstad Holding nv:企業の戦略・SWOT・財務情報
    Randstad Holding nv - Strategy, SWOT and Corporate Finance Report Summary Randstad Holding nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • athenahealth Inc (ATHN):製薬・医療:M&Aディール及び事業提携情報
    Summary athenahealth Inc (athenahealth) is a provider of cloud-based business services and mobile applications for medical groups and health system. The company offers network-enabled services for revenue cycle management and medical billing, electronic health records (EHR), patient engagement, popu …
  • Mitsubishi Motors Corporation (7211):企業の財務・戦略的SWOT分析
    Mitsubishi Motors Corporation (7211) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆